The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
Open accessAbstract
Angiogenic processes depend on the precise coordination of different cell types and a complex exchange of signals, many of which derive from new specific components of the provisional, angiogenesis-related, extracellular matrix (ECM). Angiogenesis-associated ECM components thus represent appealing targets for the selective delivery of therapeutic molecules to newly forming tumor vessels. Results of a previous study indicated that a high affinity recombinant antibody (L19) to ED-B, a domain contained in the angiogenesis-associated isoform of fibronectin (B-FN), selectively and efficiently targets tumor vessels. The present study shows that a fusion protein between L19 and interleukin 2 (L19–IL-2) mediates the selective delivery and concentration of IL-2 to tumor vasculature, thereby leading to a dramatic enhancement of the therapeutic properties of the cytokine. By contrast, IL-2 fused to an irrelevant recombinant antibody used as a control fusion protein showed neither accumulation in tumors nor therapeutic efficacy. Tumors in mice treated with L19–IL-2 were significantly smaller compared to those in animals treated with saline, the control fusion protein, or IL-2 alone (P = .003, .003, and .002, respectively). Moreover, no significant differences in size were observed among the tumors from the different control groups (using the control fusion protein, a mixture of IL-2 and L19, or saline alone). Immunohistochemical analysis of tumor infiltrates demonstrated a significantly higher number of T lymphocytes, natural killer cells, and macrophages, as well as increased interferon-γ (IFN-γ) accumulation, in tumors from animals treated with L19–IL-2 compared to tumors from control groups. The fact that ED-B is 100% homologous in human and mouse, thus ensuring that L19 reacts equally well with human and murine antigen, should ultimately expedite transfer of this reagent to clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Blood Vessel Formation: What Is Its Molecular Basis?
Folkman, J., & D'Amore, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81810-3 · Cited by 1,215
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R., Shapiro, L., Arap, W., & Ruoslahti, E. I. (2000) · PubMed · Cited by 966
The IL-2/IL-2 receptor system: A current overview
Taniguchi, T. (1993) · Cell · doi:10.1016/0092-8674(93)90152-g · Cited by 761
αv Integrins as receptors for tumor targeting by circulating ligands
Pasqualini, R., Koivunen, E., & Ruoslahti, E. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-542 · Cited by 744
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Cited by
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Self-citationVascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Role of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Metadata
- Authors
- Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-03-01
- Volume
- 99
- Issue
- 5
- Pages
- 1659-1665
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2043944189
- Cited by
- 296
- References
- 34
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. https://app.cochat.ai/papers/10.1182/blood.v99.5.1659
- The paper
- Carnemolla, B., Borsi, L., Balza, E., Castellani, P., Meazza, R., Berndt, A., Ferrini, S., Kosmehl, H., Neri, D., & Zardi, L. (2002). Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. https://doi.org/10.1182/blood.v99.5.1659
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.